Systems and methods for performing biological assays are provided herein. The systems and methods determine one or more characteristics of a nucleic acid amplification sample based on a modified optical property of the sample.

A technique that uses nanotechnology to electrically detect and identify RNA sequences without the need for using enzymatic amplification methods or fluorescent labels. The technique may be scaled into large multiplexed arrays for high-throughput and rapid screening. The technique is further able to differentiate closely related variants of a given bacterial or viral species or strain. This technique addresses the need for a quick, efficient, and inexpensive bacterial and viral detection and identification system.

A technique that uses nanotechnology to electrically detect and identify RNA sequences without the need for using enzymatic amplification methods or fluorescent labels. The technique may be scaled into large multiplexed arrays for high-throughput and rapid screening. The technique is further able to differentiate closely related variants of a given bacterial or viral species or strain. This technique addresses the need for a quick, efficient, and inexpensive bacterial and viral detection and identification system.

Provided is a method for detecting analyte in a sample, which method comprises: (a) contacting the sample with a peptide nucleic acid (PNA) probe; (b) performing an electrochemical impedance spectrometry (EIS) measurement on the sample; (c) determining the presence, absence, quantity and/or identity of the analyte from the EIS measurement;
wherein the analyte comprises nucleic acid;
and wherein the quantity of analyte in the sample when the sample is taken is substantially the same as the quantity of analyte in the sample when the sample is subjected to the EIS measurement.

Provided is a method for detecting analyte in a sample, which method comprises: (a) contacting the sample with a peptide nucleic acid (PNA) probe; (b) performing an electrochemical impedance spectrometry (EIS) measurement on the sample; (c) determining the presence, absence, quantity and/or identity of the analyte from the EIS measurement;
wherein the analyte comprises nucleic acid;
and wherein the quantity of analyte in the sample when the sample is taken is substantially the same as the quantity of analyte in the sample when the sample is subjected to the EIS measurement.

Methods and kits for detecting the presence of at least one target DNA sequence with or without a modification in a DNA molecule are provided.

Methods and kits for detecting the presence of at least one target DNA sequence with or without a modification in a DNA molecule are provided.

The present invention belongs to the field of nucleic acid detection, particularly in-vitro diagnostics. The invention concerns amongst others the amplification of at least one or more target nucleic acid that may be present in at least one sample using an inventive control, which comprises a particle comprising a polycationic compound and a nucleic acid. The present invention relates also to uses of the inventive controls, methods for the preparation, diagnostic tools and kits.

The present invention belongs to the field of nucleic acid detection, particularly in-vitro diagnostics. The invention concerns amongst others the amplification of at least one or more target nucleic acid that may be present in at least one sample using an inventive control, which comprises a particle comprising a polycationic compound and a nucleic acid. The present invention relates also to uses of the inventive controls, methods for the preparation, diagnostic tools and kits.

The present description relates to a method for binding to a target molecule having an aldehyde compound derived from N-(2-aminoethyl)pyrrole, which compound also has a moiety of interest, to compounds (conjugates) obtained by this method, having both the target molecule and the moiety of interest and to novel substances derived from N-(2-aminoethyl)pyrrole. In one embodiment, the compound has the formula of Formula II ##STR00001##
wherein R1, R2 and R3 independently are H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein R4, R5, R6, R7 and R8 independently are H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -LM, wherein L is absent or is a linker and M is a moiety of interest selected from a nucleotide, an oligonucleotide, a peptide, a label, a cytotoxic agent, a partner of a binding pair and a functional group, wherein two of R4, R5, R6, R7, and R8 optionally are linked to form a substituted or unsubstituted cycloalkyl or a substituted or unsubstituted heterocycloalkyl, and T is a target molecule selected from the group consisting of a solid phase, a polypeptide, a protein, a carbohydrate, a nucleotide and a nucleic acid, with the proviso that at least one of R4, R5, R6, R7 or R8 is -LM.